NASDAQ · RVMD
Revolution Medicines, Inc.
$190.27+$1.55 (+0.82%)
Revolution Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.18% below the high.
Loading market information…
NASDAQ · EXAS · USD
Stock price, earnings
Quote as of Mar 23, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Exact Sciences Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Exact Sciences Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:40 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $708.66M-1.14% vs estimate |
| Q2 2024 | Jul 31, 2024 | -$0.09+75.68% vs estimate | $699.26M+1.34% vs estimate |
|---|
| Q1 2024 | May 8, 2024 | -$0.50-5.27% vs estimate | $637.52M+1.62% vs estimate |
|---|
THE ANALYST VIEW
41 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$190.27+$1.55 (+0.82%)
Revolution Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.18% below the high.
$37.52+$0.41 (+1.1%)
Roivant Sciences Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.72% below the high.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$19.20+$0.43 (+2.29%)
Viatris Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.13% below the high.
$165.78+$0.45 (+0.27%)
Revvity, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.94% below the high.
$215.48+$1.32 (+0.62%)
ICON Public Limited Company’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$70.73-$0.09 (-0.13%)
BridgeBio Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
$16.20+$0.43 (+2.73%)
Summit Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.58% below the high.
